EmpiraMed, Inc.

Maynard, Massachusetts 01754

0 studies enrolling now · 1 studies all time

What they study most

Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung

Studies at this site

• A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors — Completed